

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: Lyudmyla Berim, MD

eRA COMMONS USER NAME (credential, e.g., agency login): BERIML

POSITION TITLE: Associate Professor, Department of Medicine, Division of Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.

EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.*)

| INSTITUTION AND LOCATION | DEGREE (if applicable) | Completion Date MM/YYYY | FIELD OF STUDY |
|---|---------------------------|-------------------------------|-------------------|
| Ternopil Medical University, Ternopil, Ukraine | MD | 7/1999 | |
| Internal Medicine Residency Kherson University Hospital, Kherson, Ukraine | | 7/2000 | |
| Internal Medicine Residency State University of New York at Buffalo, NY | | 6/2009 | |
| Hematology/Oncology Fellowship, Roswell Park Cancer Institute and SUNY Buffalo, NY | | 7/2012 | |

A. Personal Statement

I am a clinical investigator and a board-certified medical oncologist with sub-specialty in gastrointestinal oncology. During the first months of my employment at CINJ I designed, wrote, and opened the Investigator Initiated Trial “Phase II Study of Modified FOLFIRINOX Alternated with Biweekly Gemcitabine plus Nab-Paclitaxel in Untreated Metastatic Adenocarcinoma of the Pancreas (ALTPANC)”. This study is open throughout RWJBH network and is actively accruing patients. I am the site PI for several industry-sponsored trials and a sub investigator in the large number of trials that are actively enrolling patients with GI malignancies. I believe that every patient with cancer diagnosis should have an opportunity to access novel therapies and management strategies by participating in clinical trials. I am committed to delivering clinical research options to patients throughout the Rutgers-Barnabas Clinical Network. I have built a large referral base within the RWJBH and with outside healthcare systems. I regularly communicate with referring surgeons, oncologists, gastroenterologists, and family physicians about mutual patients’ care and update them on CINJ’s current and upcoming clinical trials. I am an active member of the Scientific Review Committee at CINJ. As a strong advocate for continued professional development, I participate annually in GI ASCO Symposium, NANETS Yearly Medical Symposium, ASCO Annual Meeting, among others. I advocate for and adhere to CINJ’s culture of equal rights and equal opportunity, respect, compassion, privacy, dignity, and morality. I am committed to continuing my service to the oncology patients, Medical School, and the Cancer Institute.

Citations:

1. Seshacharyulu P, Halder S, Nimmakayala R, Rachagani S, Chaudhary S, Atri P, Chirravuri-Venkata R, Ouellette MM, Carmicheal J, Gautam SK, Vengoji R, Wang S, Li S, Smith L, Talmon GA, Klute K, Ly Q, Reames BN, Grem JL, Berim L, Padussis JC, Kaur S, Kumar S, Ponnusamy MP, Jain M, Lin C, Batra SK. Disruption of FDPS/Rac1 axis radiosensitizes pancreatic ductal adenocarcinoma by attenuating DNA damage response and immunosuppressive signalling. EBioMedicine. 2022 Jan;75:103772. doi: 10.1016/j.ebiom.2021.103772. Epub 2021 Dec 28. PMID: 34971971; PMCID: PMC8718746.

2. Neibart SS, Mamidanna S, Chundury A, Sayan M, Alexander HR, August DA, Berim LD, Boland PM, Grandhi MS, Gulhati P, Hochster HS, Langan RC, Spencer KR, Kennedy TJ, Deek MP, Jabbour SK. Outcomes of patients with borderline resectable and resectable pancreatic adenocarcinoma treated with neoadjuvant three-week course chemoradiotherapy using capecitabine-based versus gemcitabine-based concurrent chemotherapy. *J Gastrointest Oncol*. 2021 Dec;12(6):2557-2566. doi: 10.21037/jgo-21-503. PMID: 35070387; PMCID: PMC8748032.
3. Qureshi, S., Berim, L. & Boland, P.M. Current Treatment Landscape for Third- or Later-Line Therapy in Metastatic Colorectal Cancer. *Curr Colorectal Cancer Rep* 17, 131–141 (2021).
4. Lin C, Verma V, Lazenby A, Ly QP, Berim LD, Schwarz JK, Madiyalakan M, Nicodemus CF, Hollingsworth MA, Meza JL, Are C, Padussis J, Grem JL. Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma. *Am J Clin Oncol*. 2019 Oct;42(10):755-760. doi: 10.1097/COC.0000000000000599. PMID: 31513018; PMCID: PMC6768754.

B. Positions, Scientific Appointments, and Honors

Division of Medical Oncology,
Robert Wood Johnson Medical School/Rutgers Cancer Institute of New Jersey
Assistant Professor of Medicine
01/02/2020 - present

Division of Hematology and Oncology
Rutgers New Jersey Medical School
Rutgers Cancer Institute of New Jersey at University Hospital
Assistant Professor of Medicine
2/2019-12/2019

University of Nebraska Medical Center
Adjunct Assistant Professor
8/2018 –3/2019

Division of Hematology and Oncology
University of Nebraska Medical Center
Assistant Professor of Medicine
8/2014 – 8/2018

Division of Hematology and Oncology
Veterans Affairs Nebraska-Western Iowa Health Care System, Omaha, NE
Staff Physician
4/2013 – 8/2018

Division of Hematology and Oncology
Creighton University, Omaha NE
Assistant Professor of Medicine
4/2013 – 7/2014

Dept. of Medical Oncology
Roswell Park Cancer Institute, Buffalo NY
Staff Physician
8/2012 – 12/2012

C. Contributions to Science

CLINICAL TRIALS; Principal Investigator; Investigator Initiated:

- a. Modified FOLFIRINOX Alternated with Biweekly Gemcitabine plus Nab-Paclitaxel in Untreated Metastatic Adenocarcinoma of the Pancreas (ALTPANC). NCT04672005. Actively Accruing.

Industry Sponsored:

- a. A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination with Immune Checkpoint Blockade for Patients with Metastatic Colorectal Cancer (GO-010). NCT05141721. Actively Accruing.
- b. BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer. NCT04264702 Completed Accrual.
- c. Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers. NCT02655822 Completed, Results published.
- d. Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE). NCT02436668. Completed, Results published.